These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 19369227

  • 1. Rational combined targeting of phosphodiesterase 4B and SYK in DLBCL.
    Kim SW, Rai D, McKeller MR, Aguiar RC.
    Blood; 2009 Jun 11; 113(24):6153-60. PubMed ID: 19369227
    [Abstract] [Full Text] [Related]

  • 2. The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT-dependent apoptosis in diffuse large B-cell lymphoma.
    Smith PG, Wang F, Wilkinson KN, Savage KJ, Klein U, Neuberg DS, Bollag G, Shipp MA, Aguiar RC.
    Blood; 2005 Jan 01; 105(1):308-16. PubMed ID: 15331441
    [Abstract] [Full Text] [Related]

  • 3. A phosphodiesterase 4B-dependent interplay between tumor cells and the microenvironment regulates angiogenesis in B-cell lymphoma.
    Suhasini AN, Wang L, Holder KN, Lin AP, Bhatnagar H, Kim SW, Moritz AW, Aguiar RCT.
    Leukemia; 2016 Mar 01; 30(3):617-626. PubMed ID: 26503641
    [Abstract] [Full Text] [Related]

  • 4. Phosphodiesterase 4B is an effective therapeutic target in colorectal cancer.
    Kim DU, Kwak B, Kim SW.
    Biochem Biophys Res Commun; 2019 Jan 15; 508(3):825-831. PubMed ID: 30528730
    [Abstract] [Full Text] [Related]

  • 5. Gene set enrichment analysis unveils the mechanism for the phosphodiesterase 4B control of glucocorticoid response in B-cell lymphoma.
    Kim SW, Rai D, Aguiar RC.
    Clin Cancer Res; 2011 Nov 01; 17(21):6723-32. PubMed ID: 21742807
    [Abstract] [Full Text] [Related]

  • 6. SYK inhibition and response prediction in diffuse large B-cell lymphoma.
    Cheng S, Coffey G, Zhang XH, Shaknovich R, Song Z, Lu P, Pandey A, Melnick AM, Sinha U, Wang YL.
    Blood; 2011 Dec 08; 118(24):6342-52. PubMed ID: 22025527
    [Abstract] [Full Text] [Related]

  • 7. FOXO1 activation is an effector of SYK and AKT inhibition in tonic BCR signal-dependent diffuse large B-cell lymphomas.
    Szydlowski M, Kiliszek P, Sewastianik T, Jablonska E, Bialopiotrowicz E, Gorniak P, Polak A, Markowicz S, Nowak E, Grygorowicz MA, Prochorec-Sobieszek M, Szumera-Cieckiewicz A, Malenda A, Lech-Maranda E, Warzocha K, Juszczynski P.
    Blood; 2016 Feb 11; 127(6):739-48. PubMed ID: 26585955
    [Abstract] [Full Text] [Related]

  • 8. Synergistic Targeting of the Regulatory and Catalytic Subunits of PI3Kδ in Mature B-cell Malignancies.
    Cooney JD, Lin AP, Jiang D, Wang L, Suhasini AN, Myers J, Qiu Z, Wölfler A, Sill H, Aguiar RCT.
    Clin Cancer Res; 2018 Mar 01; 24(5):1103-1113. PubMed ID: 29246942
    [Abstract] [Full Text] [Related]

  • 9. SYK regulates mTOR signaling in AML.
    Carnevale J, Ross L, Puissant A, Banerji V, Stone RM, DeAngelo DJ, Ross KN, Stegmaier K.
    Leukemia; 2013 Nov 01; 27(11):2118-28. PubMed ID: 23535559
    [Abstract] [Full Text] [Related]

  • 10. SYK inhibition modulates distinct PI3K/AKT- dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas.
    Chen L, Monti S, Juszczynski P, Ouyang J, Chapuy B, Neuberg D, Doench JG, Bogusz AM, Habermann TM, Dogan A, Witzig TE, Kutok JL, Rodig SJ, Golub T, Shipp MA.
    Cancer Cell; 2013 Jun 10; 23(6):826-38. PubMed ID: 23764004
    [Abstract] [Full Text] [Related]

  • 11. Syk activation of phosphatidylinositol 3-kinase/Akt prevents HtrA2-dependent loss of X-linked inhibitor of apoptosis protein (XIAP) to promote survival of Epstein-Barr virus+ (EBV+) B cell lymphomas.
    Hatton O, Phillips LK, Vaysberg M, Hurwich J, Krams SM, Martinez OM.
    J Biol Chem; 2011 Oct 28; 286(43):37368-78. PubMed ID: 21908615
    [Abstract] [Full Text] [Related]

  • 12. Syk-induced phosphatidylinositol-3-kinase activation in Epstein-Barr virus posttransplant lymphoproliferative disorder.
    Hatton O, Lambert SL, Phillips LK, Vaysberg M, Natkunam Y, Esquivel CO, Krams SM, Martinez OM.
    Am J Transplant; 2013 Apr 28; 13(4):883-890. PubMed ID: 23398911
    [Abstract] [Full Text] [Related]

  • 13. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma.
    Chen L, Monti S, Juszczynski P, Daley J, Chen W, Witzig TE, Habermann TM, Kutok JL, Shipp MA.
    Blood; 2008 Feb 15; 111(4):2230-7. PubMed ID: 18006696
    [Abstract] [Full Text] [Related]

  • 14. MicroRNA-124 regulates glucocorticoid sensitivity by targeting phosphodiesterase 4B in diffuse large B cell lymphoma.
    Kim J, Jeong D, Nam J, Aung TN, Gim JA, Park KU, Kim SW.
    Gene; 2015 Mar 01; 558(1):173-80. PubMed ID: 25576220
    [Abstract] [Full Text] [Related]

  • 15. Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia.
    Buchner M, Baer C, Prinz G, Dierks C, Burger M, Zenz T, Stilgenbauer S, Jumaa H, Veelken H, Zirlik K.
    Blood; 2010 Jun 03; 115(22):4497-506. PubMed ID: 20335218
    [Abstract] [Full Text] [Related]

  • 16. Spleen tyrosine kinase (Syk), a novel target of curcumin, is required for B lymphoma growth.
    Gururajan M, Dasu T, Shahidain S, Jennings CD, Robertson DA, Rangnekar VM, Bondada S.
    J Immunol; 2007 Jan 01; 178(1):111-21. PubMed ID: 17182546
    [Abstract] [Full Text] [Related]

  • 17. The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKCdelta and proteasome-dependent regulation of Mcl-1 expression.
    Baudot AD, Jeandel PY, Mouska X, Maurer U, Tartare-Deckert S, Raynaud SD, Cassuto JP, Ticchioni M, Deckert M.
    Oncogene; 2009 Sep 17; 28(37):3261-73. PubMed ID: 19581935
    [Abstract] [Full Text] [Related]

  • 18. Psoralidin inhibits LPS-induced iNOS expression via repressing Syk-mediated activation of PI3K-IKK-IκB signaling pathways.
    Chiou WF, Don MJ, Liao JF, Wei BL.
    Eur J Pharmacol; 2011 Jan 10; 650(1):102-9. PubMed ID: 20951127
    [Abstract] [Full Text] [Related]

  • 19. Distinct role of spleen tyrosine kinase in the early phosphorylation of inhibitor of kappaB alpha via activation of the phosphoinositide-3-kinase and Akt pathways.
    Lee YG, Chain BM, Cho JY.
    Int J Biochem Cell Biol; 2009 Apr 10; 41(4):811-21. PubMed ID: 18775507
    [Abstract] [Full Text] [Related]

  • 20. Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia.
    Buchner M, Fuchs S, Prinz G, Pfeifer D, Bartholomé K, Burger M, Chevalier N, Vallat L, Timmer J, Gribben JG, Jumaa H, Veelken H, Dierks C, Zirlik K.
    Cancer Res; 2009 Jul 01; 69(13):5424-32. PubMed ID: 19549911
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.